CRISPR-Cas Diagnostics for Field-Deployable SARS-CoV-2 Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current coronavirus testing methods are inefficient, lacking in sensitivity and specificity, and require extensive sample processing, making them unsuitable for rapid detection and field deployment, particularly during outbreaks like COVID-19, where time-sensitive and accurate diagnostics are crucial.
Innovation Solution
A single-reaction composition using thermostable CRISPR Cas proteins and isothermal amplification reagents, such as LAMP, for extraction-free detection of coronavirus nucleic acids, enabling rapid and accurate identification of SARS-CoV-2 without the need for nucleic acid isolation, utilizing guide polynucleotides and collateral nuclease activity to generate a detectable signal.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional coronavirus testing methods are used, then detection accuracy can be achieved, but processing time is extended and operational complexity increases
Solution Approach 1:
The patent combines nucleic acid extraction, isothermal amplification, and CRISPR-based detection into a single integrated reaction system. The extraction-free lysis buffer directly processes clinical samples while simultaneously enabling amplification and detection, eliminating sequential processing steps and reducing total turnaround time while maintaining diagnostic accuracy
Solution Approach 2:
The patent employs pre-designed guide RNAs and optimized reaction conditions that are prepared in advance. The isothermal amplification primers and CRISPR guide sequences are specifically tailored for SARS-CoV-2 targets, allowing the system to rapidly detect viral nucleic acids without requiring complex sample preparation or multiple processing stages
2Measurement precision
If conventional coronavirus testing methods are used, then detection accuracy can be achieved, but operational complexity and sample processing requirements increase
Solution Approach 1:
The patent eliminates the separate nucleic acid extraction step by using an extraction-free lysis buffer that directly releases viral RNA from clinical samples. This simplifies the workflow by removing complex extraction protocols, centrifugation steps, and purification columns, making the test suitable for point-of-care settings while preserving detection sensitivity
Solution Approach 2:
The patent creates a multi-functional reaction system where a single buffer performs lysis, protects nucleic acids, enables isothermal amplification, and supports CRISPR detection. The thermostable Cas proteins and guide RNAs provide universal detection capability for multiple SARS-CoV-2 variants, reducing the need for variant-specific reagents and simplifying operational procedures
3Productivity
If rapid detection is implemented, then processing time is reduced, but detection sensitivity and specificity may deteriorate
Solution Approach 1:
The patent uses isothermal amplification at constant temperature (65°C) instead of thermal cycling, which accelerates the amplification process while maintaining product yield. The CRISPR-Cas13a system provides real-time detection of amplified viral RNA through collateral cleavage activity, enabling rapid sensitivity assessment without extending incubation periods
Solution Approach 2:
The patent employs guide RNAs as intermediaries that specifically bind to SARS-CoV-2 nucleic acid sequences and activate Cas13a collateral activity. This intermediary mechanism ensures high specificity by requiring precise guide-target complementarity, while the amplification step boosts signal intensity to maintain sensitivity even in rapid processing conditions
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for rapid, sensitive, and specific detection of coronavirus nucleic acids, reducing processing time to under 2 hours and achieving high accuracy, even in field-deployable settings, with the potential to significantly improve outbreak response and patient management.
Implementation Method 1
a type VI CRISPR-Cas system, comprising: a thermostable Cas protein; at least one guide polynucleotide comprising a guide sequence capable of binding a target sequence and designed to form a complex with the thermostable Cas protein
Implementation Method 2
wherein the Cas protein exhibits collateral nuclease activity and cleaves the detection construct once activated by the target sequence
Implementation Method 3
at least one guide polynucleotide comprising a guide sequence capable of binding a target sequence and designed to form a complex with the thermostable Cas protein
Implementation Method 4
isothermal amplification reagents
Data Source
AI summary
Systems and methods for rapid diagnostics related to the use of CRISPR effector systems and optimized guide sequences for detection of coronavirus, including multiplex lateral flow diagnostic devices and methods of use, are provided.